English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2022 → 2023: -49.14%
Price change 2023 → 2024: -44.26%
Price change 2024 → 2025: 71.77%
Price change 2025 → 2026: -72.96%
Price change 2026 (year to date): -75.45%
Financial growth
Revenue CAGR (7 years): N/A
Earnings CAGR (7 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.12
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -1.74
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 74.08% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="PEPG" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| PepGen Inc. | – | 0.12 | – | 🔒 |
| Bastide Le Confort Médical S.A. | 20.1 | 5.70 | +10.3 % | – |
| Transgene S.A. | – | 0.02 | −20.1 % | – |
| Onward Medical N.V. | – | 0.25 | +34.5 % | – |
| Valerio Therapeutics S.A. | – | 3.67 | −13.5 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by PepGen Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 133 m | 182 m | 110 m | 120 m | 148 m |
| Total Debt | 0 | 24.5 m | 20.1 m | 18.7 m | 17.0 m |
| Net Debt | -133 m | -157 m | -60.7 m | -30.8 m | -43.5 m |
| Equity | 133 m | 180 m | 108 m | 119 m | 147 m |
| Total assets | 144 m | 217 m | 143 m | 151 m | 174 m |
| Operating cash flow | -22.6 m | -59.3 m | -69.0 m | -82.4 m | -81.6 m |
| Investments (capex) | 500,000 | 3.8 m | 2.6 m | 497,000 | 264,000 |
| Free cash-flow | -23.1 m | -63.0 m | -71.6 m | -82.9 m | -81.9 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Analyst consensus and forecasts
What the financial analysts covering PepGen Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 9 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
PepGen Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 11/11/2026. Expected EPS: -0.27.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about PepGen Inc.
What is the PepGen Inc. share price?
Latest recorded price: 2.47 USD on 06/11/2026, for a market cap of 171 m USD.
When does PepGen Inc. report its next earnings?
The next release is expected on 11/11/2026. EPS expected by analysts: -0.27.
What do analysts say about PepGen Inc.?
Out of 6 analysts: 5 buy or strong buy, 0 hold, 1 sell or strong sell.
Is PepGen Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US7133171055).
How many employees does PepGen Inc. have?
79 full-time employees according to the latest published profile.
Who runs PepGen Inc.?
James G. McArthur is the company's chief executive.